PREFEREnce-based randomized evaluation of treatment modalities in low or early intermediate-risk prostate cancer

Eur Urol. 2015 Jan;67(1):1-2. doi: 10.1016/j.eururo.2014.09.016. Epub 2014 Sep 27.

Authors

Thomas Wiegel¹, Michael Stöckle², Detlef Bartkowiak³

Affiliations

¹ Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany. Electronic address: [email protected].
² Department of Urology, University Hospital Homburg/Saar, Homburg, Germany.
³ Department of Radiation Oncology, University Hospital Ulm, Ulm, Germany.

PMID: 25269383
DOI: 10.1016/j.eururo.2014.09.016

No abstract available

Publication types

Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents, Hormonal / therapeutic use
Brachytherapy
Disease Progression
Humans
Male
Patient Preference*
Patient Selection*
Prognosis
Prostatectomy
Prostatic Neoplasms / pathology
Prostatic Neoplasms / therapy*
Survival Rate
Watchful Waiting

Substances

Antineoplastic Agents, Hormonal